Efficacy, safety, and tolerability of abatacept in the management of rheumatoid arthritis

about

Efficacy, safety, and tolerability of abatacept in the management of rheumatoid arthritis

Item

http://www.wikidata.org/entity/Q38993229

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh

2009年學術文章

@zh-hant

name

Efficacy, safety, and tolerability of abatacept in the management of rheumatoid arthritis

@en

type

Item

label

Efficacy, safety, and tolerability of abatacept in the management of rheumatoid arthritis

@en

prefLabel

Efficacy, safety, and tolerability of abatacept in the management of rheumatoid arthritis

@en

P1476

Efficacy, safety, and tolerability of abatacept in the management of rheumatoid arthritis

@en

P2093

Joseph R Lutt

http://www.w3.org/2001/XMLSchema#string

P2860

Anakinra for rheumatoid arthritis

The MOS 36-ltem Short-Form Health Survey (SF-36)

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

Assessment of rheumatoid arthritis using a modified scoring method on digitized and original radiographs.

Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials.

Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark II.

Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis.

Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials.

Cytokine pathways and joint inflammation in rheumatoid arthritis.

P304

17-35

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/OARRR.S4536

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2009-05-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27789979

http://www.w3.org/2001/XMLSchema#string

P932

5074723

http://www.w3.org/2001/XMLSchema#string